WAIKOLOA, Hawaii — Brolucizumab 6 mg demonstrates a favorable benefit-risk profile in the treatment of patients with diabetic macular edema, according to a presentation at Retina 2022.
“To conclude on the summary of all three of these clinical trials, brolucizumab 6 mg was noninferior to aflibercept in respect to visual acuity at week 52 with fewer injections in the KESTREL and KITE study,” Michael S. Ip, MD, said during a presentation offering topline summarization of the KESTREL, KITE and KINGFISHER trials investigating the safety and efficacy of brolucizumab (Novartis). “With